Merck’s Newly Approved Capvaxive Could Have Edge Over Prevnar 20 In Adults

 
• By Jessica Merrill

The 21-valent pneumococcal vaccine will face an entrenched competitor in Pfizer’s Prevnar 20, but Merck believes Capvaxive has a competitive advantage because it protects against serotypes specific to adults.

pneumococcal vaccine
Merck & Co.'s 21-valent pneumococcal vaccine was approved by FDA • Source: Shutterstock

More from New Products

More from Scrip